February 23, 2023 11:02 AM EST
People
Startups

Third Rock shrinks an­oth­er biotech as Cedil­la re­struc­tures, CEO and CBO de­part

Kyle LaHucik

Senior Reporter

Biotech in­cu­ba­tor and in­vestor Third Rock Ven­tures has pruned an­oth­er one of its off­shoots by re­plac­ing the CEO, re­struc­tur­ing and look­ing for part­ners for lead as­sets.

Cedil­la Ther­a­peu­tics, launched in 2018 with $56 mil­lion from the VC firm, is “en­gaged in sev­er­al strate­gic dis­cus­sions re­lat­ed to its lead pro­grams,” a Third Rock spokesper­son told End­points News via email. Part­ner Neil Ex­ter, a 16-year vet­er­an of the in­vest­ment shop, has re­placed Alexan­dra Glucks­mann as CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

TRENDING NOW

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

In one of JP Mor­gan's first biotech bets, En­laza rais­es $100M for its per­ma­nent­ly bind­ing pro­tein drugs

Lil­ly boosts sales guid­ance by $2B, but GLP-1 sup­ply con­straints still a fo­cus

No­var­tis hands Pep­tiDream $180M up­front to ex­tend ra­dio­phar­ma dis­cov­ery pact

DNA se­quenc­ing firm PacBio to lay off work­ers and shut­ter San Diego of­fice

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times